Related Experiment Video
Updated: Sep 18, 2025
05:30
Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies
Published on: January 31, 2025
622
Plasma Proteomic Profiling Yields a High-Performance Biomarker Panel for Predicting a Poor Prognosis in Patients with
Zhijin Zhang1, Huqin Yang1, Leyi Gao1
1Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
Journal of Proteome Research
|June 23, 2025
Summary
Researchers developed a new plasma biomarker panel to predict COVID-19 mortality. This panel, including interleukin 8 and osteoprotegerin, shows promise in identifying patients at high risk of death during hospitalization.
Area of Science:
- * Medicine
- * Immunology
- * Proteomics
Background:
- * The COVID-19 pandemic highlighted the need for accurate tests to predict disease severity and mortality.
- * Traditional clinical assessments often lack sufficient predictive power for short-term mortality in severe COVID-19 cases.
Purpose of the Study:
- * To identify reliable biomarkers for predicting in-hospital mortality in COVID-19 patients.
- * To develop and validate a novel plasma biomarker panel for COVID-19 mortality prediction.
Main Methods:
- * Plasma proteomics using the Olink platform was performed on samples from COVID-19 patients (fatal, severe, moderate/mild) and healthy controls.
- * Receiver operating characteristic (ROC) curves and logistic regression were used to assess biomarker accuracy.
- * A novel biomarker panel was developed and validated in an independent external cohort.
Main Results:
- * 75 proteins were found to be differentially expressed among the four groups, indicating immune system dysregulation in fatal COVID-19.
- * A novel plasma biomarker panel, including interleukin 8 and osteoprotegerin, demonstrated strong predictive value (AUC 0.791 and 0.781).
- * The panel's predictive capability was successfully validated in an external cohort.
Conclusions:
- * Standardized proteomic assays can yield a reliable prediction panel for COVID-19 mortality.
- * The developed biomarker panel can aid in predicting mortality during hospitalization for COVID-19 patients.
- * This tool can assist clinicians in risk stratification and management of COVID-19 patients.
